SSRIs and Adjacent Medications

0:01Juno: One thing first. Nothing you hear in the next half hour or so tells you what to take. It tells you what to ask. The person who answers is your doctor or your psychiatrist, and this episode exists so that appointment goes better.

0:31Beck: This is The Observatory, from Lone Star Telehealth. Every other day, one book, until we run out.

0:40Juno: So there's no book on the table. What's this one, and who's it for?

0:46Beck: Our second reference episode. The medicines prescribed for depression and anxiety, for adults with ADHD or autism, and for the people around them.

0:58Juno: And I'm back in the patient's chair.

1:01Beck: You are. Someone with an appointment soon, where a prescription for low mood or worry might be on the table.

1:08Juno: And your answers come from where?

1:12Beck: PubMed, the federal index of medical research, and OpenEvidence, a search tool made for clinicians. Whatever either one turns up, we read the paper itself before it goes in.

1:25Beck: There's a one-page sheet on the episode page, too. Today's questions, space to write, and a small daily tracker.

1:34Juno: And the house rule.

1:35Beck: We don't rank them, here or anywhere else. When a study compares medicines, we say what it measured and leave it there.

1:44Juno: And if I only care about one medicine?

1:48Beck: Skip to its chapter. They're marked on the episode page.

1:52Juno: Who else is this for?

1:54Beck: Partners, parents of grown children, close friends. Anyone who might end up in the waiting room, or on the phone with the pharmacy.

2:03Juno: Will it be a wall of numbers?

2:06Beck: Fewer than usual. A couple per chapter, the ones worth asking about. The rest are on the episode page with their sources.

2:14Juno: One problem already. Every medicine today has two names, and the second one sounds like a spell.

2:22Beck: Then you say the brands. I'll handle the spells.

2:25Juno: Fair trade.

2:28Juno: Why make this episode for people with ADHD or autism in particular?

2:33Beck: Because depression and anxiety keep close company with both.

2:37Juno: How close?

2:39Beck: For autism, a review pooled dozens of studies of autistic adults. About four in ten had had an anxiety disorder at some point in their lives.

2:50Juno: So that's not a rare pairing.

2:53Beck: No. Depression wasn't far behind. One caution on method: many of those studies drew on clinic samples, and the authors flag that as a limit.

3:03Juno: And ADHD?

3:05Beck: Large registry, survey and insurance studies, hundreds of thousands of adults with ADHD. Their odds of an anxiety disorder or major depression were four to five times those of adults without it.

3:20Juno: So having both is ordinary. Not some strange exception.

3:26Beck: Ordinary. Which is why it gets an episode of its own.

3:37Juno: My doctor mentioned Zoloft. What's that, in plain words?

3:42Beck: Zoloft is sertraline. It's an SSRI, short for selective serotonin reuptake inhibitor.

3:49Juno: And without the long name?

3:52Beck: It leaves more serotonin, one of the brain's signaling chemicals, available between nerve cells.

3:58Juno: Who else is in that family?

4:01Beck: Lexapro, which is escitalopram.

4:04Juno: Mm-hm.

4:05Beck: And Prozac, which is fluoxetine. There are a few more, built along the same lines.

4:11Juno: What are they prescribed for?

4:13Beck: Depression, and a range of anxiety conditions. Zoloft's label includes panic disorder, social anxiety disorder and PTSD.

4:25Beck: Lexapro's label includes generalized anxiety disorder.

4:28Beck: Zoloft's also covers OCD, and a severe form of premenstrual mood symptoms.

4:35Juno: Do they work? Plainly.

4:38Beck: For depression, the largest analysis pooled hundreds of double-blind trials, more than a hundred thousand adults. Every antidepressant it looked at did better than placebo.

4:51Juno: Every single one.

4:53Beck: On direction, yes. The authors rated most trials at moderate risk of bias, and the certainty of the evidence ran from moderate to very low.

5:03Juno: So solid on the direction, softer on the details.

5:09Beck: That's fair. And it's an average, over the first couple of months. It can't tell anyone how they, in particular, will respond.

5:18Juno: And for anxiety?

5:20Beck: For generalized anxiety, a network analysis of drug trials in adults found several SSRIs and SNRIs did better than placebo.

5:30Juno: So they help on average, and the trials can't say who.

5:35Beck: Right. Which one fits you is the prescriber's question, not a study's.

5:48Juno: Say I fill it. What's the first month like?

5:52Beck: Usually a starting dose and a check-in before anything changes. Most of the month is noticing.

6:00Juno: When would I feel something?

6:03Beck: Sometimes sooner than people expect. An analysis of the early weeks of SSRI trials, thousands of adults, found improvement over placebo by the end of the first week.

6:17Juno: I'd always heard you wait a month or more.

6:20Beck: The early change is small. It kept building for weeks after that, more slowly. So the full picture takes a while.

6:28Juno: So a little, early, and more with time.

6:34Beck: As a group average, yes. Not a promise for any one person.

6:39Beck: Picture someone starting an SSRI. In those first weeks, they're keeping an eye on three things at once: stomach, sleep and mood.

6:50Juno: And the mood part?

6:51Beck: On average, it builds gradually. Which is why a daily note beats trying to remember how the week went.

6:59Juno: And what does the month feel like, side effects wise?

7:03Beck: Zoloft's label lists nausea, loose stools, an upset stomach, less appetite and sweating among the common ones.

7:13Beck: Picture a queasy stomach some mornings, and sleep that's a little off. That's the kind of thing to write down.

7:20Juno: Off which way?

7:21Beck: Either. Trouble sleeping and daytime sleepiness both showed up more than on placebo. Morning or night dosing is a fair question to ask.

7:33Juno: Is there anything they'll ask me before I start?

7:36Beck: Family history, for one. The label tells prescribers to screen for any personal or family history of bipolar disorder first.

7:45Juno: Why that?

7:47Beck: In someone with bipolar disorder, an antidepressant can set off a manic or mixed episode. So a relative's diagnosis is worth bringing.

7:57Juno: And the side effect nobody asks about.

8:00Beck: Sexual side effects. Lower desire, trouble with arousal, and orgasm that's delayed or doesn't happen. They're on the label.

8:10Juno: How common?

8:11Beck: A study in Spain asked outpatients on antidepressants directly, with a questionnaire, instead of waiting for them to raise it. More than half reported some sexual side effect.

8:24Juno: That's a lot of people not mentioning it.

8:28Beck: That was the authors' point. It gets missed unless someone asks. It's on the sheet, in plain words, so you don't have to find them in the room.

8:38Juno: And if a side effect is too much?

8:41Beck: Then it's a call to the prescriber, not a quiet stop. Stopping suddenly has its own problems, and we'll get to those.

8:50Beck: And that's the tracker's job. A line a day: dose and time, sleep, stomach, mood, and anything new.

8:59Juno: So the first month is for noticing and saying it out loud. Even the awkward part.

9:14Juno: What if it's Effexor instead?

9:17Beck: That's an SNRI. Effexor is venlafaxine.

9:21Juno: And Cymbalta?

9:23Beck: Duloxetine. And Pristiq, which is desvenlafaxine, is the third name you'll hear.

9:30Juno: How are they different from the SSRIs?

9:33Beck: They act on serotonin and on a second messenger, norepinephrine. That's the N in the name.

9:40Juno: Same uses?

9:42Beck: Overlapping. All three are approved for depression. Effexor's label adds several anxiety disorders.

9:49Beck: Cymbalta's adds generalized anxiety, and some pain conditions that last.

9:54Juno: Pain. I didn't expect that.

9:58Beck: Nerve pain from diabetes, fibromyalgia, and chronic muscle and joint pain. For someone living with both, that can come up.

10:07Juno: So if pain is part of the picture, say so.

10:11Beck: Yes. It's the sort of thing people leave out because it feels like a different appointment.

10:16Juno: Anything to watch that's different?

10:19Beck: Blood pressure. All three labels call for it to be checked while you're on them.

10:25Juno: So a cuff on the arm is part of the routine.

10:28Beck: It is. And Cymbalta's label advises against it with heavy drinking or chronic liver disease. Say so if either applies.

10:37Juno: Same suicide warning as the others?

10:40Beck: The same boxed warning, yes. It gets its own chapter later.

10:45Juno: So, a close relative of the SSRIs, with a blood pressure check built in.

10:58Juno: Where does Wellbutrin fit? I remember it from episode five.

11:03Beck: Bupropion. Back then it was the off-label guest for ADHD. Here it's on home ground: it's approved for depression.

11:12Juno: Only depression?

11:14Beck: One long-acting form is also approved to prevent seasonal depression, the kind that comes back each winter. And a version has been approved to help people quit smoking.

11:25Juno: Not anxiety?

11:27Beck: No. Anxiety isn't on its label.

11:31Juno: How is it different from the others?

11:34Beck: It works on dopamine and norepinephrine rather than serotonin. So it's built differently from everything so far. Why a prescriber reaches for it depends on the person, and it's their call.

11:46Juno: Risks?

11:48Beck: Seizures. The risk rises with the dose. The label rules it out for people with a seizure disorder, or a history of anorexia or bulimia.

11:58Juno: Even from years ago?

12:00Beck: For the eating disorders, current or past, the label says. For its ADHD story, episode five has the evidence.

12:08Juno: And the suicide warning?

12:10Beck: It carries the same boxed warning as every antidepressant.

12:15Juno: So, a depression medicine first, and the seizure question gets a full answer.

12:28Juno: I've heard of ones people take mostly for sleep, or for anxiety. What are those?

12:36Beck: A handful. Remeron, which is mirtazapine, is approved for depression. Its label stands out for two things: drowsiness and appetite.

12:46Juno: How drowsy?

12:48Beck: In its trials, more than half the people taking it reported sleepiness.

12:53Juno: So it's an evening pill.

12:56Beck: Its label says evening, before sleep. A bigger appetite and weight gain are worth asking about too.

13:05Juno: And the one people take to sleep?

13:07Beck: Trazodone. It's approved for depression. At low doses, it's also prescribed off-label for sleep.

13:14Juno: Does it work for that?

13:16Beck: A Cochrane review found a few small, short trials. They suggested a small improvement in how people rated their sleep, on limited evidence. Whether it fits is the prescriber's call.

13:29Juno: BuSpar?

13:30Beck: Buspirone. It's approved for anxiety, it isn't a controlled substance, and its label reports no sign of abuse or dependence.

13:39Juno: Does it work right away?

13:41Beck: Not like a sedative. Its trials ran for weeks, and a Cochrane review found it beat placebo for generalized anxiety.

13:50Juno: And Vistaril?

13:52Beck: Hydroxyzine. It's an antihistamine, approved for the symptoms of anxiety. A Cochrane review found it beat placebo across five small trials with a high risk of bias.

14:04Juno: An antihistamine. Like an allergy medicine?

14:09Beck: Same broad family, yes.

14:11Juno: And the trials were small, and shaky. Got it.

14:16Beck: Drowsiness is the side effect the review flagged. Its label also flags a heart rhythm effect, so the prescriber will want your full list.

14:26Juno: And the older ones I've heard mentioned?

14:28Beck: Two older families, the tricyclics and the MAOIs. Both are still prescribed, and both bring more interactions to manage. MAOIs add food rules, and they can't be combined with stimulants.

14:43Beck: One MAOI's own label describes it as rarely the first antidepressant someone tries.

14:49Juno: So the list runs past the famous names, and each one has its own trade.

15:03Juno: Xanax, Klonopin, Ativan. Why do people talk about those so differently?

15:11Beck: They're benzodiazepines. Xanax is alprazolam.

15:16Juno: Go on.

15:16Beck: Klonopin is clonazepam.

15:19Juno: And Ativan?

15:21Beck: Lorazepam. They work quickly, and that speed is likely a big part of why they're used.

15:28Juno: Do they work, though?

15:30Beck: For panic disorder, a Cochrane review of two dozen trials found them better than placebo in the short term. The evidence was rated low quality.

15:41Juno: Short term.

15:42Beck: Yeah. Short term. Those trials didn't measure long-term benefit, or dependence.

15:49Juno: And dependence is the worry I hear about.

15:52Beck: The FDA treats it as a real one. The boxed warning on this class covers misuse, addiction, physical dependence, and withdrawal reactions.

16:02Juno: Even at the dose I'm given?

16:04Beck: The FDA says even at recommended doses, yes. It also notes most of these are meant for periods of weeks or months.

16:13Juno: So stopping takes a plan.

16:16Beck: It does. The FDA's guidance is a gradual taper worked out with the prescriber, not a sudden stop.

16:25Juno: Anything they shouldn't be mixed with?

16:28Beck: Opioids, including some cough medicines. A separate boxed warning names extreme sleepiness, slowed breathing, coma and death. Alcohol and other sedating drugs belong in the same conversation.

16:41Juno: So the prescriber needs to know what I drink, too.

16:46Beck: All of it. And if someone's coming off a benzodiazepine, buspirone's label says it won't ease that withdrawal.

16:53Juno: Fast and useful in the short run. And the exit gets planned before the start.

17:08Juno: I'm already on Adderall. Can one of these go alongside it?

17:13Beck: People do take both, and checking the interactions is the prescriber's job. Here's what's on the record.

17:20Beck: Amphetamine labels warn about serotonin syndrome, a reaction to too much serotonin activity, when combined with SSRIs or SNRIs.

17:30Juno: Okay.

17:31Beck: And some antidepressants slow how the body clears amphetamine.

17:35Juno: What does that mean in practice?

17:38Beck: It means the prescriber needs your whole list, and knows what to watch for. It doesn't mean the pairing is off the table.

17:46Juno: Has anyone studied people taking both?

17:49Beck: One study used South Korean insurance records. More than seventeen thousand adults with ADHD and depression, all taking methylphenidate, the medicine in Ritalin.

18:00Juno: And adding an SSRI?

18:03Beck: Didn't raise the rate of the side effects they tracked.

18:06Juno: Only Ritalin-type medicines, though?

18:09Beck: Only methylphenidate. Amphetamines weren't studied, so it can't speak for Adderall.

18:15Juno: What about everyday painkillers?

18:18Beck: Worth a mention. Zoloft's label says aspirin and anti-inflammatory pain relievers can add to bleeding risk, and so can blood thinners.

18:27Juno: So the Advil in the kitchen drawer goes on the list.

18:31Beck: It does.

18:32Juno: And if someone's pregnant, or hoping to be?

18:36Beck: Start that conversation early, with the prescriber and whoever's caring for the pregnancy. One large study looked at nearly a million pregnancies in US Medicaid records.

18:48Juno: Looking for what?

18:50Beck: Heart defects. Once depression itself was accounted for, antidepressants early in pregnancy weren't tied to a meaningful rise.

18:59Juno: That's one question answered.

19:01Beck: One. Others depend on the medicine. Perinatal psychiatrists, also called reproductive psychiatrists, work on exactly this, and you can ask to see one.

19:12Juno: And for autistic adults. Is anything different?

19:16Beck: The fair answer is that the trial evidence is thin. A review of dozens of trials in autistic people found many medication trials aimed at autism itself, not at depression or anxiety.

19:30Juno: And those?

19:31Beck: Didn't help. Until there's more, the authors' advice was to follow the evidence for non-autistic people.

19:39Juno: I've heard autistic people can be more sensitive to side effects.

19:43Beck: People say so. We couldn't find good trial evidence either way. An older Cochrane review of SSRIs in autism found no benefit in children, signs of harm, and only small, uncertain adult studies.

19:59Juno: So what do you do with that?

20:01Beck: Lean on the tracker. If a new medicine changes how sound, light or your own body feels, write it down and say it.

20:11Juno: Other medicines, a pregnancy, an autistic nervous system. Say all of it, first.

20:27Juno: I've read there's a warning about suicide on these. What does it say?

20:33Beck: Every antidepressant carries an FDA boxed warning. It says that in short-term studies, these medicines increased suicidal thoughts and behaviors in children, teenagers and young adults.

20:46Juno: Young meaning what?

20:48Beck: Under twenty-five.

20:49Juno: Where did that line come from?

20:52Beck: From the FDA pooling the placebo-controlled trials. Hundreds of them in adults, tens of thousands of people, with separate trials in children and teenagers.

21:03Juno: And what did the pooling show?

21:06Beck: In young adults, about five more people per thousand had suicidal thoughts or behaviors than on placebo.

21:15Juno: So uncommon. But not nothing.

21:19Beck: Right. And in the trials in children and teenagers, nobody died by suicide. The signal was in thoughts and behaviors.

21:27Juno: And above that age?

21:30Beck: No increase in the pooled trials. In older adults, fewer than on placebo.

21:36Juno: So the warning is about age.

21:39Beck: Mostly. And about short trials. The label says it's unknown whether the risk carries on with longer use.

21:47Juno: So what does it ask people to do?

21:49Beck: Watch closely, at any age, for worsening or new suicidal thoughts. Especially in the first few months, and after a dose change.

22:00Juno: Why put it on every box if it's uncommon?

22:04Beck: Because it's serious, and the warning's job is to make sure someone is watching during those early months.

22:10Juno: So does it mean a young adult shouldn't take one?

22:14Beck: The warning doesn't say that. It says watch. Whether to start is between that person and their prescriber.

22:21Juno: Watched by whom?

22:23Beck: You, the prescriber, and anyone you trust to tell you they've noticed a change. That's a good job for a partner or a friend.

22:33Beck: If you're in crisis, call or text 988.

22:39Juno: So it asks for close watching, early on. That's the plain version.

22:52Juno: What if I want to stop? Can I just stop?

22:56Beck: Not suddenly, and not on your own. The labels recommend a gradual reduction over an abrupt stop, and the taper gets planned with the prescriber.

23:07Juno: What happens if you stop all at once?

23:10Beck: Discontinuation symptoms. Dizziness, nausea, poor sleep, irritability. Some people describe brief sensations like small electric shocks.

23:21Juno: How common is that?

23:23Beck: A meta-analysis pooled dozens of studies of people stopping an antidepressant, or stopping a placebo.

23:30Juno: A placebo?

23:32Beck: Yeah. A placebo. Some people get symptoms stopping a sugar pill. Subtract that, and the authors put it at about one in six or seven people.

23:43Juno: So most people don't. But enough that it needs a plan.

23:48Beck: And severe symptoms were uncommon.

23:51Juno: What if my old symptoms come back while I taper?

23:55Beck: Tell the prescriber. Returning symptoms and discontinuation symptoms can look alike, and the review's authors flagged that same difficulty.

24:05Juno: How long does a taper take?

24:07Beck: The labels don't set one length. They say gradual, and the schedule is something you and the prescriber build together.

24:16Juno: Is it the same for all of these?

24:19Beck: Not necessarily. Each medicine has its own label, which is one more reason to ask about yours by name.

24:26Juno: And staying on. For how long?

24:29Beck: That's the prescriber's call. One trial asked it head on, in UK general practices. People who'd had repeat episodes or long use, and felt well enough to stop.

24:42Beck: They were randomly assigned to stay on, or to taper onto a placebo without knowing which.

24:48Juno: And?

24:49Beck: Over a year, more than half of the placebo group relapsed. Noticeably fewer did among those who stayed on.

24:58Juno: So feeling better and being finished aren't always the same thing.

25:04Beck: Not for that group. Which makes it a question for the sheet: how will we know when it's time, and how would we taper?

25:12Juno: Starting and stopping both get planned. Neither one happens on a whim.

25:19Juno: So. I walk in with the sheet, my full list and my questions. And if we start something, a line a day after that.

25:28Beck: That's someone a prescriber can work with.

25:31Juno: My question list has more chapters than this episode.

25:35Beck: Sure.

25:36Beck: Next time, a book again. Sari Solden, Women with Attention Deficit Disorder. We've spent nine episodes on how these brains work. Now, who got missed.

25:49Juno: Back to the shelf, then.

25:50Juno: Okay. Next book.

25:52Beck: Next book. Go.

25:54Beck: All of this was reported from the published evidence, and none of it was a recommendation. Your questions belong with your medical doctor or your psychiatrist. They know you, and they can prescribe. We can't do either.

26:09Juno: Before you fill anything, check the price on GoodRx. The Observatory is a show from Lone Star Telehealth. Logan Williamson is a Licensed Professional Counselor in Texas and Louisiana. This was education. It wasn't counseling, and it's no substitute for care. The chapters and every source are on the episode page.

26:39Juno: One last note. Both voices here are synthetic. Neither of us is a person or a licensed clinician, and nothing in this episode was about you. The script was drafted with AI assistance, then edited and approved by Logan Williamson at Lone Star Telehealth. Logan Williamson is a Licensed Professional Counselor in Texas and Louisiana.